Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 3/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735870 | 0.96 | CYP3A4 (0.36) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6739255 | 0.91 | FYN (0.39) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6738550 | 0.89 | CYP3A4 (0.41) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6734343 | 0.87 | CYP3A4 (0.40) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6741557 | 0.86 | MAPT (0.32) | — | |
| SCHEMBL6735986 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6736586 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6737466 | 0.86 | CYP3A4 (0.41) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6740421 | 0.85 | CYP3A4 (0.37) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 | |
| SCHEMBL6737916 | 0.85 | CYP3A4 (0.37) | CYP3A4CYP2C8S1PR3CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6682785-B2 | A FLUOROANTHRACENE COMPOUNDS; HEAT RESISTANCE, RADIATION RESISTANCE, PHOTOSTABILITY | CLARIANT FINANCE (BVI) LIMITED (VG) | 2004-01-27 | — | — | US | disclosed |
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | CLARIANT INTERNATIONAL LTD. | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118749-A1 | A fluoroanthracene compounds; heat resistance, radiation resistance, photostability | HSF1, ABCC1, FLNA | CYP3A4 411/4885CYP2C8 218/4885S1PR3 4480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.